

Distribution agreement signed with Perigon Health 360 for US remote patient monitoring

Melbourne, Australia – 20 July 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote patient monitoring and data management solutions, is pleased to announce it has signed a distribution agreement for US patient monitoring with Perigon Health 360 (“Perigon”) to sell the Hailie® platform, including its new, next generation sensors.

Perigon’s world-class proprietary platform, Medesto, is an enterprise drug and therapy monitoring platform that consolidates remote monitoring services into one portal enabling health care providers to pursue reimbursement for respiratory and chronic care management services. Especially designed to collaborate directly with patients, Medesto facilitates real-time medication adherence and health marker tracking for precision patient-tailored care that benefits patients with serious diseases.

Adherium’s transformative Hailie digital product portfolio has been incorporated into Perigon’s Medesto drug and therapy monitoring platform, enabling optimum patient management and treatment by automatically transmitting data directly to the patient’s healthcare provider, while improving medication adherence and reducing costs to healthcare systems.

“Given the rapid development of remote patient monitoring and telehealth, particularly accelerated by the COVID-19 pandemic, this distribution agreement marks a major step in the execution of the commercial strategy for Adherium’s Hailie platform in the US. With our sophisticated devices and integrated platform, the Company is well positioned to lead the market”, commented Adherium Chief Executive Officer, Rick Legleiter.

Perigon Health has successfully integrated the Hailie Software Development Kit (SDK) with the Medesto platform and Perigon’s first purchase orders for both Adherium’s new, next generation and current digital sensors have been shipped for patients in the US. In addition, patient enrollment and set-up for remote patient monitoring has commenced representing a significant milestone journey towards



helping the often-overlooked patients suffering from severe asthma and COPD.

Co-Founder and CEO of Perigon, Ted Mills, said: “Innovation is crucial to our future, and we’re extremely pleased to be collaborating with Adherium to support their continued focus on improving clinical outcomes and reducing exacerbations, hospital admissions and health system costs in managing respiratory patient populations. This partnership will expand our product portfolio and enable both companies to continue to achieve commercial success accelerating momentum in the digital healthcare industry.”

The signing of this distribution agreement for an initial three-year term follows Adherium’s recent announcement of the Helicon Health distribution agreement, strengthening the Company’s growth strategy.

-ENDS-

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium’s Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium’s own broad range of sensors connected to respiratory medications. Adherium’s Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at www.adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries: WE Communications
WE-AUAdherium@we-worldwide.com